Cassava will stop developing simufilam for Alzheimer’s this year after a Phase 3 trial failed to improve cognition and daily ...

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory ...

(Reuters) -Cassava Sciences said on Tuesday it will discontinue the development of its experimental treatment simufilam for ...

Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).

The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...